Naftifine topical - Sebela Pharmaceuticals

Drug Profile

Naftifine topical - Sebela Pharmaceuticals

Alternative Names: NAFT-500; NAFT-600; NAFT-900; Naftifine HCl; Naftifine hydrochloride; Naftin Cream 2%; Naftin Gel 2%

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merz Pharma
  • Developer Sebela Pharmaceuticals
  • Class Allylamines; Antifungals
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Tinea corporis; Tinea cruris; Tinea pedis

Most Recent Events

  • 02 Jun 2017 No recent reports on development identified - Phase-III for Tinea cruris (In adolescents, In children) in Dominican Republic, Honduras, and Belize (Topical,Cream,1%)
  • 08 Sep 2016 Merz Pharmaceuticals withdraws a phase II trial in Tinea capitis (In children) in USA (Topical,Foam,3%) (NCT02658292)
  • 12 Jan 2016 Merz Pharmaceuticals plans a phase II trial for Tinea capitis (In children) in USA (Topical,Foam,3%) (NCT02658292)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top